Efficacy, Dose-Response, Onset, Peak, and Duration

Key Points

• Efficacy refers to the ability of a drug to produce the desired therapeutic effect; when protocol options exist, nurses select the drug with the most appropriate anticipated response.
• Dose-response relationship: As dose increases, both therapeutic response and toxicity potential increase; the relationship defines the therapeutic index (effective dose range).
• Therapeutic window: The range between the effective concentration (EC) and the toxic concentration (TC) of a drug — the “perfect dose” zone where the drug achieves its intended effect without causing toxicity.
• Narrow therapeutic index drugs (e.g., warfarin, digoxin, lithium, phenytoin, aminoglycosides) require close monitoring; even small dose increases can produce toxicity.
• Onset = when drug effect begins; peak = maximum drug concentration and greatest therapeutic effect; duration = how long the therapeutic effect lasts.
• Peak and trough levels: Drawn for IV drugs requiring titration (e.g., IV aminoglycosides); peak = highest serum level after administration; trough = lowest level just before next dose. Nurses must coordinate administration timing with blood draw schedules.
• Steady state is reached when drug intake equals drug elimination, producing a stable therapeutic concentration.
• Half-life determines dosing frequency: short half-life → more frequent dosing; long half-life → less frequent dosing.

Pathophysiology

Dosing considerations determine the clinical effect a medication has on a patient. Nurses must understand how efficacy, dose-response, onset, peak, duration, and steady state interact to safely administer medications, time doses effectively, and evaluate therapeutic response.

Classification

Efficacy

Efficacy refers to the capacity of a drug to produce the desired therapeutic response. When a provider’s protocol allows a choice among medication options, the nurse selects the drug with the anticipated efficacy appropriate for the patient’s current clinical presentation (e.g., selecting a more potent analgesic for severe pain vs. a milder agent for mild discomfort).

Dose-Response Relationship

The dose-response relationship describes how the clinical effect of a drug changes as the dose changes:

• As dose increases, therapeutic response generally increases — up to a maximum (ceiling) effect.
• As dose increases beyond therapeutic range, the potential for toxicity also increases.
• This relationship is used to determine the therapeutic index: the effective dose range in which the drug produces therapeutic effects without causing unacceptable toxicity.

When dose-response is graphed (dose on x-axis, response on y-axis), the slope of the curve represents the therapeutic index. A steep slope indicates a narrow therapeutic index — small dose increases produce large changes in response, increasing toxicity risk.

Therapeutic Window

The therapeutic window is the range of drug concentrations that produces a therapeutic effect without causing toxicity:

• Effective Concentration (EC): The minimum drug level required to produce a therapeutic effect.
• Toxic Concentration (TC): The drug level at which toxic effects begin to occur.
• Between EC and TC is the therapeutic window — the target range for drug dosing.
• Example: Warfarin’s therapeutic window is monitored using the INR (international normalized ratio). Too much warfarin → bleeding (antidote: vitamin K); too little → clotting. Nurses monitor INR vigilantly to keep the drug within the therapeutic window.

Therapeutic Index and Narrow Therapeutic Window Drugs

The therapeutic index (TI) is a quantitative measure of drug safety — the ratio between the toxic dose and the therapeutic dose:

• High (large) TI: Wide therapeutic window between effective and toxic concentrations → drug is relatively safe.
• Low (small) TI / Narrow therapeutic index: Small margin between effective and toxic concentrations → even minor dose changes can produce toxicity.
• Examples of narrow therapeutic index drugs: warfarin, digoxin, lithium, phenytoin, aminoglycoside antibiotics.
• These drugs require serum drug level monitoring (peak/trough levels, INR, etc.) and close clinical surveillance. Dosage is often titrated (adjusted based on serum levels) to maintain the drug within its therapeutic window.
• Example: Phenytoin — patients starting therapy for seizure control undergo frequent peak and trough level monitoring to reach steady state at a therapeutic dose without crossing into toxicity.

Peak and Trough Monitoring

For IV medications with narrow therapeutic windows (particularly IV aminoglycoside antibiotics such as gentamicin), serum peak and trough levels are drawn to guide titration:

• Peak level: Drawn after administration when the drug is at its highest concentration in the bloodstream (confirms adequate therapeutic level).
• Trough level: Drawn immediately before the next scheduled dose when the drug is at its lowest concentration (confirms the drug has cleared sufficiently to avoid accumulation).
• Titration: The prescriber adjusts the dose based on measured serum levels to keep the drug consistently within the therapeutic window — above the effective concentration (therapeutic effect achieved) and below the toxic concentration (toxicity avoided).
• Nursing responsibility: When administering IV medications requiring peak/trough levels, the nurse must plan the medication administration timing precisely to align with the scheduled blood draws; errors in timing invalidate the results and can lead to incorrect dose adjustments.

Onset of Action

Onset is the time from drug administration until the drug begins to produce a measurable therapeutic effect. Onset is strongly influenced by the route of administration:

• IV route: Fastest onset — drug enters systemic circulation immediately, bypassing absorption.
• Oral/enteral route: Slower onset — drug must be absorbed through the GI tract and undergo first-pass hepatic metabolism before reaching systemic circulation.
• Example: An IV diuretic (furosemide IV) begins working within 5 minutes; the same drug given orally takes 30–60 minutes to produce diuresis.

Peak

Peak refers to the point at which drug concentration in the body is at its maximum and the patient experiences the greatest therapeutic effect:

• Peak timing varies by drug and route; it is documented in drug references.
• Example: Oral ibuprofen reaches peak plasma levels (and maximum pain relief) approximately 1–2 hours after administration.

Duration

Duration refers to the length of time that a drug continues to produce its desired therapeutic effect:

• Duration is related to the drug’s half-life and elimination rate.
• When duration ends, plasma drug concentration has fallen below the minimum effective concentration.
• Example: Oral acetaminophen has a duration of approximately 4–6 hours — patients typically require a repeat dose at this interval for continued pain relief.

Half-Life and Dosing Frequency

Half-life determines how frequently a drug must be administered to maintain therapeutic levels:

• Short half-life → drug eliminated quickly → shorter duration → more frequent dosing required to maintain therapeutic blood levels.
• Long half-life → drug eliminated slowly → longer duration → less frequent dosing adequate.
• Example: Oxycodone immediate-release (IR) is dosed every 4–6 hours (short duration) for rapid pain relief; oxycodone extended-release (ER) is dosed every 12 hours (sustained release with longer duration) for continuous pain management.

Steady State

Steady state is the point at which the amount of drug entering the body (each dose) equals the amount being eliminated between doses, resulting in a stable, consistent plasma drug concentration:

• At steady state, the patient experiences optimal, predictable therapeutic effect.
• Steady state is typically reached after approximately 4–5 half-lives of a drug.
• If the patient’s elimination capacity changes (e.g., renal impairment develops), steady state is disrupted and drug accumulation (toxicity) may occur.

Nursing Assessment

NCLEX Focus

NCLEX frequently tests onset/peak/duration in scenarios involving timing of medication administration relative to patient activities (e.g., giving an analgesic before physical therapy, timing insulin with meals). Know that IV route = fastest onset. Recognize narrow therapeutic index drugs as requiring close monitoring. For peak/trough questions: peak is drawn after administration at highest level; trough is drawn immediately before the next dose at lowest level. Nurses are responsible for coordinating medication administration timing with blood draws.

• Assess the patient’s pain level, vital signs, or target symptom before administering medications — determine whether the drug’s efficacy matches the clinical need.
• Assess the route and calculate expected onset: adjust timing to ensure peak effect coincides with patient need (e.g., administer analgesic before a painful procedure or physical therapy session).
• Assess meal timing when administering medications with meal-dependent effects (e.g., insulin must be timed to carbohydrate intake to prevent hypoglycemia).
• Identify whether the prescribed drug has a narrow therapeutic index; confirm monitoring parameters (drug levels, INR, serum creatinine) are in place.
• Assess current renal and hepatic function — impairment can alter elimination and shift steady-state equilibrium toward toxicity.
• When administering IV medications that require peak/trough monitoring (e.g., gentamicin), verify the scheduled blood draw times and plan medication administration accordingly — incorrect timing produces inaccurate results and may lead to unsafe dose adjustments.

Nursing Interventions

• Time medications strategically: Administer analgesics, anti-emetics, and other comfort medications with enough lead time for onset so that peak effect occurs when most needed.
• Insulin and carbohydrate synchronization: When a patient refuses a meal or cannot eat, assess whether to hold or modify insulin — administering insulin at the intended time without carbohydrate intake risks hypoglycemia (onset of NPH insulin is 1–3 hours after administration).
• Monitor narrow therapeutic index drugs closely: Check serum drug levels and signs of toxicity at appropriate intervals; anticipate that organ impairment will narrow the margin further.
• Educate patients on drug duration: Explain when to expect their medication to wear off and when a repeat dose is appropriate (e.g., acetaminophen duration 4–6 hours for pain management).
• Recognize sustained-release formulations: Never crush or split extended-release tablets — doing so eliminates the controlled-release mechanism and delivers the full dose rapidly, potentially causing toxicity.
• Titrate narrow TI drugs based on serum levels: For drugs such as phenytoin or aminoglycosides, coordinate with the provider and pharmacist to adjust doses based on measured peak/trough values until the patient reaches steady state within the therapeutic window.

Narrow Therapeutic Index Drugs

Warfarin, digoxin, lithium, phenytoin, and aminoglycosides have narrow therapeutic windows. Small changes in dose, drug interactions, or organ function can shift plasma levels from therapeutic to toxic. These drugs require scheduled serum monitoring and careful clinical assessment for signs of toxicity at every encounter.

Pharmacology

Concept	Definition	Clinical Example	Nursing Implication
Efficacy	Capacity to produce desired therapeutic effect	Morphine has higher efficacy for severe pain than acetaminophen	Select drug with appropriate efficacy for the clinical situation
Therapeutic window	Range between effective concentration (EC) and toxic concentration (TC)	Warfarin: monitored by INR; too much → bleeding; too little → clotting	Monitor INR; dose adjustments target the therapeutic window
Therapeutic index	Ratio between toxic and therapeutic dose; high TI = safer	Digoxin (narrow TI): small dose increase → toxicity; phenytoin: frequent peak/trough monitoring	Monitor serum levels; titrate dose; watch for early toxicity signs
Onset	Time from administration to first measurable effect	IV furosemide onset 5 min vs. oral 30–60 min	Select route based on urgency; time medication relative to patient needs
Peak	Time of maximum drug concentration and effect	Oral ibuprofen peaks in 1–2 hours	Anticipate peak timing for patient comfort and procedure scheduling
Trough	Lowest drug level, drawn immediately before next dose	Gentamicin trough drawn just before next IV dose	Coordinate medication timing with blood draw schedule; inaccurate timing = inaccurate results
Duration	How long therapeutic effect lasts	Oral acetaminophen: 4–6 hours	Educate patients; schedule re-dosing before duration ends for persistent need
Half-life/dosing	Short half-life → frequent dosing; long half-life → less frequent	Oxycodone IR q4–6h vs. Oxycodone ER q12h	Match dosing interval to half-life; never crush ER formulations
Steady state	Drug in = drug out → stable plasma concentration	Most drugs reach steady state in 4–5 half-lives	Expect therapeutic effect to stabilize after several doses; reassess if organ function changes

Clinical Judgment Application

Clinical Scenario

A post-operative patient rates pain 7/10 at 0500. Physical therapy (PT) is scheduled for 0900. The patient has acetaminophen 625 mg PO ordered every 4 hours as needed.

• Recognize Cues: Pain 7/10 at rest, PT at 0900 (4 hours away), PRN acetaminophen available.
• Analyze Cues: Acetaminophen’s peak effect occurs approximately 1–1.5 hours after oral administration; its duration is 4–6 hours. Administering at 0500 would produce peak around 0600–0630, with duration potentially fading by 0900–1100 depending on the patient. Administering closer to 0730 would align peak effect with PT at 0900.
• Prioritize Hypotheses: The critical issue is timing medication to maximize therapeutic effect during the highest-demand period (PT session).
• Generate Solutions: Administer acetaminophen at approximately 0730 (1–1.5 hours before PT) to align peak analgesic effect with PT; document pain reassessment before and after PT.
• Take Action: Assess current pain level, administer acetaminophen at 0730, educate the patient on timing rationale, reassess at 0900 before PT begins.
• Evaluate Outcomes: Patient reports pain tolerable (3–4/10) during PT; participates in rehabilitation without significant distress.

Related Concepts

• pharmacokinetics-and-pharmacodynamics — ADME stages determine onset, peak, duration, and steady state.
• metabolism-pharmacokinetics — Half-life is determined by hepatic metabolism rate; liver impairment prolongs duration.
• excretion-pharmacokinetics — Renal excretion rate affects elimination half-life and steady state.
• insulin — Insulin onset, peak, and duration are critical for matching administration to carbohydrate intake.
• opioids — Onset/peak/duration differences between immediate-release and extended-release opioids determine dosing intervals and toxicity risk.

Self-Check

1. What is the difference between drug onset, peak, and duration? Give one clinical example of how each concept affects nursing practice.
2. A patient is prescribed digoxin. Why does this drug’s narrow therapeutic index require special nursing vigilance, and what monitoring parameters should be in place?
3. NPH insulin has an onset of 1–3 hours. A patient refuses breakfast at 0730. The morning NPH dose was given at 0700. What is the nurse’s priority concern and action?
4. A patient receiving IV gentamicin needs a peak and trough level drawn. The trough is scheduled immediately before the 1400 dose. The nurse administers the 1400 dose before the trough is drawn. What is the clinical consequence, and what should the nurse have done?
5. Explain the difference between a therapeutic window and a therapeutic index. Why do drugs with a narrow therapeutic index require dose titration based on serum drug levels?